Literature DB >> 32239453

Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor.

Rocío Aller1,2, Rebeca Sigüenza3, María Pina3, Cristina Laserna1, Beatriz Antolín2, Beatriz Burgueño2, Miguel Durà2, Olatz Izaola1,4, David Primo1,4, Daniel Antonio de Luis5,6.   

Abstract

BACKGROUND AND AIMS: The prevalence of the non-alcoholic fatty liver disease (NAFLD) in developed countries is up to 30% of the general population, and 50% of patients present type 2 diabetes mellitus (DM2). Fibrosis is the most important prognostic factor in NAFLD. The aim of this study was to search evidence for an early diagnosis of liver fibrosis in subjects with DM2 and to evaluate potential risk and protective factors.
METHODS: This study was conducted among 160 diabetic patients with NAFLD proven biopsy. Anthropometric assessments, laboratory test, liver histological features and follow-up of a Mediterranean diet were evaluated.
RESULTS: Diabetic patients with liver fibrosis showed a greater number of positive metabolic criteria than diabetic patients without liver fibrosis. Patients with hepatic fibrosis have a lower score on the PREDIMED test (9.0 (2.4) vs. 6.2 (2.3); p < 0.05). Diabetic patients with liver fibrosis showed higher glucose levels (delta: 10.1 (4.5) mg/dl), fasting insulin levels (delta: 3.1 (1.5) UI/L), HOMA-IR (delta: 2.1 (0.3) units) and HbA1c (delta: 0.6 (0.2)%). Non-invasive tests showed a higher score (non-alcoholic fatty liver disease fibrosis score and fibrosis-4) in liver fibrosis subjects than no liver fibrosis subjects. A logistic regression analysis adjusted by age, gender, HbA1c and body mass index showed independent significant direct association between liver fibrosis and homeostatic model assessment of insulin resistance as indicator of insulin resistance (odds ratio (OR) = 1.53: 95% confidence interval (CI): 1.1-2.2; p = 0.026) and inverse association with PREDIMED score as an indicator of adherence to Mediterranean diet (OR = 0.6; 95% CI: 0.4-0.8; p = 0.01).
CONCLUSION: In patients with DM2, insulin resistance is an independent risk factor associated with liver fibrosis, and the adherence of a Mediterranean diet is a protective factor associated with absence of liver fibrosis.

Entities:  

Keywords:  Fibrosis; Liver biopsy; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus

Mesh:

Year:  2020        PMID: 32239453     DOI: 10.1007/s12020-020-02268-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  1 in total

Review 1.  Fatty liver disease in diabetes mellitus.

Authors:  Harikrashna B Bhatt; Robert J Smith
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

  1 in total
  12 in total

1.  Commentary on "Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial".

Authors:  Francesco Baratta; Daniele Pastori; Maria Del Ben
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 7.293

2.  The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018.

Authors:  Ji Cheol Bae; Lauren A Beste; Kristina M Utzschneider
Journal:  Endocrinol Metab (Seoul)       Date:  2022-06-21

3.  Gender Differences in the Context of Obstructive Sleep Apnea and Metabolic Diseases.

Authors:  Fátima O Martins; Sílvia V Conde
Journal:  Front Physiol       Date:  2021-12-14       Impact factor: 4.566

4.  Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study.

Authors:  Dae-Jeong Koo; Mi Yeon Lee; Inha Jung; Sun Joon Moon; Hyemi Kwon; Se Eun Park; Eun-Jung Rhee; Won-Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2021-10-21

5.  Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.

Authors:  Yi-Wen Shi; Fang-Ping He; Jin-Jun Chen; Hong Deng; Jun-Ping Shi; Cai-Yan Zhao; Yu-Qiang Mi; Zheng-Sheng Zou; Yong-Jian Zhou; Fu-Sheng Di; Rui-Dan Zheng; Qin Du; Jia Shang; Rui-Xu Yang; Branko Popovic; Bi-Hui Zhong; Jian-Gao Fan
Journal:  J Clin Transl Hepatol       Date:  2021-04-23

6.  The molecular mechanism of Ligusticum wallichii for improving idiopathic pulmonary fibrosis: A network pharmacology and molecular docking study.

Authors:  Xiaozheng Wu; Wen Li; Zhenliang Luo; Yunzhi Chen
Journal:  Medicine (Baltimore)       Date:  2022-02-11       Impact factor: 1.817

Review 7.  Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches.

Authors:  Angelo Armandi; Jörn M Schattenberg
Journal:  Nutrients       Date:  2021-06-08       Impact factor: 5.717

Review 8.  Gut Microbiome and Organ Fibrosis.

Authors:  Carolina F F A Costa; Benedita Sampaio-Maia; Ricardo Araujo; Diana S Nascimento; Joana Ferreira-Gomes; Manuel Pestana; Maria J Azevedo; Ines S Alencastre
Journal:  Nutrients       Date:  2022-01-14       Impact factor: 5.717

9.  Selected Organ and Endocrine Complications According to BMI and the Metabolic Category of Obesity: A Single Endocrine Center Study.

Authors:  Ewa Malwina Milewska; Ewelina Szczepanek-Parulska; Martyna Marciniak; Aleksandra Krygier; Agnieszka Dobrowolska; Marek Ruchala
Journal:  Nutrients       Date:  2022-03-20       Impact factor: 5.717

10.  Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.

Authors:  Judith van Dalem; Johanna H M Driessen; Andrea M Burden; Coen D A Stehouwer; Olaf H Klungel; Frank de Vries; Martijn C G J Brouwers
Journal:  Hepatology       Date:  2021-08-22       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.